Cayuga Closes $8M Seed Funding

▤ Summary

Cayuga Biotech closed an $8 million seed round to advance CAY001 into Phase 1 clinical testing. The company is developing a synthetic polyphosphate-silica nanoparticle treatment for life-threatening hemorrhage. The funding will support safety, pharmacokinetic, and pharmacodynamic evaluation in healthy volunteers, with proof-of-concept data targeted for 2026. The article also highlights support from investors and the Defense Health Agency for the program's potential to address a major unmet medical need.

$ Funding

▦ Linked Companies